A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) or B-Cell Lymphoma

Trial Profile

A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) or B-Cell Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2014

At a glance

  • Drugs GNKG 168 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Biomarker
  • Sponsors SBI Biotech
  • Most Recent Events

    • 18 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Jul 2012 Official title amended as reported by Oregon Health and Science University Institutional Review Board.
    • 21 Mar 2012 New source identified and integrated (IRB00006550; Oregon Health and Science University Institutional Review Board).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top